American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
Regier, DA, Narrow, WE, Rae, DS, Manderscheid, RW, Locke, BZ, Goodwin, FK. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993; 50(2): 85–94.
Saha, S, Chant, D, Welham, J, McGrath, J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005; 2(5): e141.
Buckley, PF, Miller, BJ, Lehrer, DS, Castle, DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009; 35(2): 383–402.
Conley, RR, Ascher-Svanum, H, Zhu, B, Faries, DE, Kinon, BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007; 90(1–3): 186–197.
Majadas, S, Olivares, J, Galan, J, Diez, T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr Psychiatry. 2012; 53(2): 145–151.
Siris, SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry. 2000; 157(9): 1379–1389.
Tollefson, GD, Sanger, TM, Lu, Y, Thieme, ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998; 55(3): 250–258.
Planansky, K, Johnston, R. Depressive syndrome in schizophrenia. Acta Psychiatr Scand. 1978; 57(3): 207–218.
Jin, H, Zisook, S, Palmer, BW, Patterson, TL, Heaton, RK, Jeste, DV. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry. 2001; 62(10): 797–803.
Reine, G, Lançon, C, Di Tucci, S, Sapin, C, Auquier, P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand. 2003; 108(4): 297–303.
Sands, JR, Harrow, M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999; 25(1): 157–171.
Birchwood, M, Mason, R, MacMillan, F, Healy, J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med. 1993; 23(2): 387–395.
Oosthuizen, P, Emsley, R, Niehaus, D, Koen, L, Chiliza, B. The relationships between depression and remission in first-episode psychosis. World Psychiatry. 2006; 5(3): 172–176.
Ishibashi, T, Horisawa, T, Tokuda, K, etal. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171–181.
Ogasa, M, Kimura, T, Nakamura, M, Guarino, J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013; 225(3): 519–530.
Nakamura, M, Ogasa, M, Guarino, J, etal. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829–836.
Nasrallah, HA, Silva, R, Phillips, D, etal. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013; 47(5): 670–677.
Meltzer, HY, Cucchiaro, J, Silva, R, etal. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011; 168(9): 957–967.
Loebel, A, Cucchiaro, J, Sarma, K, etal. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013; 145(1–3): 101–109.
Citrome, L, Cucchiaro, J, Sarma, K, etal. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165–176.
Stahl, SM, Cucchiaro, J, Simonelli, D, Hsu, J, Pikalov, A, Loebel, A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013; 74(5): 507–515.
Cates, LN, Roberts, AJ, Huitron-Resendiz, S, Hedlund, PB. Effects of lurasidone in behavioral models of depression: role of the 5-HT7 receptor subtype. Neuropharmacology. 2013; 70: 211–217.
Loebel, A, Cucchiaro, J, Silva, R, etal. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014; 171(2): 160–168.
Loebel, A, Cucchiaro, J, Silva, R, etal. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014; 171(2): 169–177.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382–389.
Hawley, CJ, Gale, TM, Sivakumaran, T. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002; 72(2): 177–184.
Citrome, L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008; 117(6): 412–419.
29. Latuda® (lurasidone hydrochloride) tablets, for oral use [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2013.
Hor, K, Taylor, M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010; 24(4 Suppl): 81–90.
Palmer, BA, Pankratz, VS, Bostwick, JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62(3): 247–253.
Schwartz, RC, Cohen, BN. Psychosocial correlates of suicidal intent among patients with schizophrenia. Compr Psychiatry. 2001; 42(2): 118–123.
Siris, SG. Suicide and schizophrenia. J Psychopharmacol. 2001; 15(2): 127–135.
Hirsch, SR, Kissling, W, Bauml, J, Power, A, O'Connor, R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry. 2002; 63(6): 516–523.
Danion, JM, Rein, W, Fleurot, O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999; 156(4): 610–616.
Breier, A, Hamilton, SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999; 45(4): 403–411.
Dollfus, S, Olivier, V, Chabot, B, Déal, C, Perrin, E. Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res. 2005; 78(2–3): 157–159.
Kasper, S. Treatment of depressive symptoms with quetiapine. Expert Rev Neurother. 2003; 3(4): 417–423.
Myers, JE, Thase, ME. Risperidone: review of its therapeutic utility in depression. Psychopharmacol Bull. 2001; 35(4): 109–129.
Emsley, RA, Buckley, P, Jones, AM, Greenwood, MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003; 17(2): 210–215.
Zhao, T, Park, TW, Yang, JC, etal. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. Int Clin Psychopharmacol. 2012; 27(4): 184–190.
Baynes, D, Mulholland, C, Cooper, SJ, etal. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res. 2000; 45(1–2): 47–56.
Zisook, S, McAdams, LA, Kuck, J, etal. Depressive symptoms in schizophrenia. Am J Psychiatry. 1999; 156(11): 1736–1743.